Making Medicines Affordable

Making Medicines Affordable PDF

Author: National Academies of Sciences, Engineering, and Medicine

Publisher: National Academies Press

Published: 2018-03-01

Total Pages: 235

ISBN-13: 0309468086

DOWNLOAD EBOOK →

Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.

Why Do Drugs Cost So Much?

Why Do Drugs Cost So Much? PDF

Author: Joe

Publisher: AuthorHouse

Published: 2008-06

Total Pages: 430

ISBN-13: 1434389901

DOWNLOAD EBOOK →

Caution! Reading this book in it's entirety may cause the following side effects: Surprise, Anger, Disbelief, and even Amusement. We begin by revealing the little known, inside workings of the pharmaceutical industry, based on the experiences of people who have worked there. Why do you think it is that your drugs cost so much? Is it because of all the high tech 'stuff' that goes into making it? Or is it something else that might shock or even anger you? What goes on behind the scenes often has nothing whatsoever to do with science. This leads to the second part which has to do with our health and the things you may not even realize are making us all sick. This is not just another 'eat right and exercise' book. You will discover information you have never heard before. There are even things that have been proven to harm you but have been covered up or ignored, and even encouraged, as long as there is money to be made. Do you like investigative reporting? Do you like history, or science fiction? Do you have a taste for the macabre? Are you concerned about declining health care, government and military cover ups, or the high cost of medicine? Written with some humor and at times a touch of sarcasm, there is a little bit of something here for everyone. You may or may not agree with some of the things in this book, but once you start reading it, your curiosity will make you want to pick it up again and again until you are finished.

The $800 Million Pill

The $800 Million Pill PDF

Author: Merrill Goozner

Publisher: Univ of California Press

Published: 2005-10-10

Total Pages: 308

ISBN-13: 9780520246706

DOWNLOAD EBOOK →

"Goozner shows how drug innovation is driven by dedicated scientists intent on finding cures for diseases, not by pharmaceutical firms, whose bottom line often takes precedence over the advance of medicine. Stories of a university biochemist who spent twenty years searching for single blood protein that later became the best-selling biotech drug in the world, a government employee who discovered the causes for dozens of crippling genetic disorders, and the Department of Energy-funded research that made the Human Genome Project possible - these accounts illustrate how medical breakthroughs actually take place.".

Why Do Drugs Cost So Much?

Why Do Drugs Cost So Much? PDF

Author: Joe and Ruth

Publisher:

Published: 2008-06-01

Total Pages: 428

ISBN-13: 9781434361592

DOWNLOAD EBOOK →

Robert Louis Rayburn is author of two prior verse by verse commentaries : EPHESIANS: The Epistle Of The Third Heaven and REVELATION: Rapture, Retribution & Rhapsody. It was through the influence of his father, the late Pastor Russell S. Rayburn, that Mr. Rayburn accepted Christ as Saviour. His father's Christian life and knowledge of the Scriptures also influenced the author to develop a love for the Word of God. Mr. Rayburn is now retired from two professions: Resource Development Manager in the transportation business; also as a Marketing Consultant with an Executive Placement Firm. He loves to share his testimony verse, which is Job 23:12, "I have esteemed the words of his mouth more than my necessary food."

Bottle of Lies

Bottle of Lies PDF

Author: Katherine Eban

Publisher: HarperCollins

Published: 2020-06-23

Total Pages: 512

ISBN-13: 0063054108

DOWNLOAD EBOOK →

A NEW YORK TIMES BESTSELLER New York Times 100 Notable Books of 2019 New York Public Library Best Books of 2019 Kirkus Reviews Best Health and Science Books of 2019 Science Friday Best Books of 2019 New postscript by the author From an award-winning journalist, an explosive narrative investigation of the generic drug boom that reveals fraud and life-threatening dangers on a global scale—The Jungle for pharmaceuticals Many have hailed the widespread use of generic drugs as one of the most important public-health developments of the twenty-first century. Today, almost 90 percent of our pharmaceutical market is comprised of generics, the majority of which are manufactured overseas. We have been reassured by our doctors, our pharmacists and our regulators that generic drugs are identical to their brand-name counterparts, just less expensive. But is this really true? Katherine Eban’s Bottle of Lies exposes the deceit behind generic-drug manufacturing—and the attendant risks for global health. Drawing on exclusive accounts from whistleblowers and regulators, as well as thousands of pages of confidential FDA documents, Eban reveals an industry where fraud is rampant, companies routinely falsify data, and executives circumvent almost every principle of safe manufacturing to minimize cost and maximize profit, confident in their ability to fool inspectors. Meanwhile, patients unwittingly consume medicine with unpredictable and dangerous effects. The story of generic drugs is truly global. It connects middle America to China, India, sub-Saharan Africa and Brazil, and represents the ultimate litmus test of globalization: what are the risks of moving drug manufacturing offshore, and are they worth the savings? A decade-long investigation with international sweep, high-stakes brinkmanship and big money at its core, Bottle of Lies reveals how the world’s greatest public-health innovation has become one of its most astonishing swindles.

The Truth About the Drug Companies

The Truth About the Drug Companies PDF

Author: Marcia Angell

Publisher: Random House Trade Paperbacks

Published: 2005-08-09

Total Pages: 354

ISBN-13: 0375760946

DOWNLOAD EBOOK →

During her two decades at The New England Journal of Medicine, Dr. Marcia Angell had a front-row seat on the appalling spectacle of the pharmaceutical industry. She watched drug companies stray from their original mission of discovering and manufacturing useful drugs and instead become vast marketing machines with unprecedented control over their own fortunes. She saw them gain nearly limitless influence over medical research, education, and how doctors do their jobs. She sympathized as the American public, particularly the elderly, struggled and increasingly failed to meet spiraling prescription drug prices. Now, in this bold, hard-hitting new book, Dr. Angell exposes the shocking truth of what the pharmaceutical industry has become–and argues for essential, long-overdue change. Currently Americans spend a staggering $200 billion each year on prescription drugs. As Dr. Angell powerfully demonstrates, claims that high drug prices are necessary to fund research and development are unfounded: The truth is that drug companies funnel the bulk of their resources into the marketing of products of dubious benefit. Meanwhile, as profits soar, the companies brazenly use their wealth and power to push their agenda through Congress, the FDA, and academic medical centers. Zeroing in on hugely successful drugs like AZT (the first drug to treat HIV/AIDS), Taxol (the best-selling cancer drug in history), and the blockbuster allergy drug Claritin, Dr. Angell demonstrates exactly how new products are brought to market. Drug companies, she shows, routinely rely on publicly funded institutions for their basic research; they rig clinical trials to make their products look better than they are; and they use their legions of lawyers to stretch out government-granted exclusive marketing rights for years. They also flood the market with copycat drugs that cost a lot more than the drugs they mimic but are no more effective. The American pharmaceutical industry needs to be saved, mainly from itself, and Dr. Angell proposes a program of vital reforms, which includes restoring impartiality to clinical research and severing the ties between drug companies and medical education. Written with fierce passion and substantiated with in-depth research, The Truth About the Drug Companies is a searing indictment of an industry that has spun out of control.

The $800 Million Pill

The $800 Million Pill PDF

Author: Merrill Goozner

Publisher: Univ of California Press

Published: 2004-04-22

Total Pages: 304

ISBN-13: 052093928X

DOWNLOAD EBOOK →

Why do life-saving prescription drugs cost so much? Drug companies insist that prices reflect the millions they invest in research and development. In this gripping exposé, Merrill Goozner contends that American taxpayers are in fact footing the bill twice: once by supporting government-funded research and again by paying astronomically high prices for prescription drugs. Goozner demonstrates that almost all the important new drugs of the past quarter-century actually originated from research at taxpayer-funded universities and at the National Institutes of Health. He reports that once the innovative work is over, the pharmaceutical industry often steps in to reap the profit. Goozner shows how drug innovation is driven by dedicated scientists intent on finding cures for diseases, not by pharmaceutical firms whose bottom line often takes precedence over the advance of medicine. A university biochemist who spent twenty years searching for a single blood protein that later became the best-selling biotech drug in the world, a government employee who discovered the causes for dozens of crippling genetic disorders, and the Department of Energy-funded research that made the Human Genome Project possible--these engrossing accounts illustrate how medical breakthroughs actually take place. The $800 Million Pill suggests ways that the government's role in testing new medicines could be expanded to eliminate the private sector waste driving up the cost of existing drugs. Pharmaceutical firms should be compelled to refocus their human and financial resources on true medical innovation, Goozner insists. This book is essential reading for everyone concerned about the politically charged topics of drug pricing, Medicare coverage, national health care, and the role of pharmaceutical companies in developing countries.

The Right Price

The Right Price PDF

Author: Peter J. Neumann

Publisher: Oxford University Press

Published: 2021

Total Pages: 273

ISBN-13: 0197512887

DOWNLOAD EBOOK →

The prescription drug market -- Proposed solutions for rising drug prices -- Measuring the value of prescription drugs -- Measuring drug value : whose job is it anyway? -- Institute for Clinical and Economic Review (ICER) -- Other US value assessment frameworks -- Do drugs for special populations warrant higher prices? -- Improving value measurement -- Aligning prices with value -- The path forward.

Bad Pharma

Bad Pharma PDF

Author: Ben Goldacre

Publisher: Macmillan

Published: 2014-04

Total Pages: 479

ISBN-13: 0865478066

DOWNLOAD EBOOK →

Argues that doctors are deliberately misinformed by profit-seeking pharmaceutical companies that casually withhold information about drug efficacy and side effects, explaining the process of pharmaceutical data manipulation and its global consequences. By the best-selling author of Bad Science.

Equitable Access to High-Cost Pharmaceuticals

Equitable Access to High-Cost Pharmaceuticals PDF

Author: Zaheer-Ud-Din Babar

Publisher: Academic Press

Published: 2018-02-27

Total Pages: 238

ISBN-13: 0128119624

DOWNLOAD EBOOK →

Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy and regulation, the Work compares and contrasts national healthcare systems to support researchers and practitioners identify optimal healthcare policy solutions. The Work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement and post-launch monitoring are considered in detail. The Work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines. Evaluates impact and efficacy of current access policies and pricing regulation of high-cost drugs Incorporates existing guidelines and recommendations by international organizations Compares and contrasts how different countries fund and police high-cost drug access Explores novel and emergent policies, including managed entry agreement, analysis of real world data and differential pricing Reviews novel pharmaceuticals of current research interest